Medtronic (MDT) Beats Stock Market Upswing: What Investors Need to Know
Medtronic (MDT) closed the most recent trading day at $87.17, moving +1.34% from the previous trading session.
Medtronic: Margin Inflection With Diabetes Spin - Key Drivers
Initiate Medtronic with Strong Buy, $161 PT, citing a structural margin inflection from Diabetes spin-off and robust innovation pipeline (120+ approvals). Street underestimates FY27 margin/EPS upside from Diabetes separation and operating leverage in Cardiac & Structural Heart—key drivers for re-rating. Valuation at 26x FY27E EPS is conservative versus peers; scenario analysis shows risk skewed to the upside, as margin catalysts execute.
Medtronic: Eyes On The Pipeline And Spin, Shares Still Cheap
I reiterate my buy rating on Medtronic, driven by solid fundamentals and an attractive valuation, despite less upside versus prior estimates. Medtronic continues to deliver steady revenue growth, robust free cash flow, and a 48-year dividend growth streak, even as sector sentiment weakens. Key risks include competitive pressures, margin threats in Diabetes and CAS, and macro headwinds like tariffs, requiring prudent management execution.
Why Is Medtronic (MDT) Up 6% Since Last Earnings Report?
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?
Medtronic: Solid Recent Performance But Better Options Available
Medtronic remains a dependable dividend aristocrat, but its long-term total shareholder returns lag significantly behind peers like Johnson & Johnson and Stryker. Despite a solid 2025 performance, the stock's recent gains stem from a low base, and it still trades well below its 2021 highs. Earnings growth is steady but uninspiring, with margin pressure and tariff risks highlighting operational challenges versus higher-quality competitors.
Medtronic Announces Intent To Spin Diabetes Business
Deal OverviewOn May 21, 2025, Medtronic plc (NYSE: MDT; $87.44, Market Capitalization: $112.1 billion), a global leader in medical technology, announced its intent to spin off its Diabetes business into a standalone entity (New Diabetes Company). This strategic move is designed to streamline Medtronic's portfolio, sharpen its focus on high-margin growth areas, and unlock shareholder value.
I'm Buying 2 Must-Own Dividend Bargains
The market continues to chase growth while ignoring once beloved income stocks. Verizon offers a compelling 6.3% dividend yield, robust free cash flow, and trades well below its historical valuation, making it attractive for conservative income investors. Medtronic provides a reliable 3.5% yield, a strong balance sheet, and growth catalysts in cardiac solutions, surgical robotics, and a value-enhancing diabetes spin-off.
Medtronic plc (MDT) Bernstein's 41st Strategic Decisions Conference - (Transcript)
Medtronic plc (NYSE:MDT ) Bernstein's 41st Strategic Decisions Conference Call May 29, 2025 11:00 AM ET Company Participants Geoff Martha - Chairman and Chief Executive Officer Thierry Pieton - Executive Vice President and Chief Financial Officer Conference Call Participants Lee Hambright - Bernstein Lee Hambright All right. Very good.
We compared 5 Dividend Aristocrats, this one came out on top
A quarter of a century of increasing dividends is a hell of a way to generate some passive income. Enter Dividend Aristocrats.
Medtronic: Diabetes Spin-Off Is Near-Term Catalyst; Rating Upgrade
Upgrading Medtronic to 'Strong Buy' with a $104 fair value, driven by the diabetes business spin-off catalyst. Divesting diabetes enables Medtronic to focus on core cardiac and surgical markets, improving operating margins and capital allocation. Recent results show robust cardiovascular growth and strong shareholder returns, with continued buybacks expected post-spin-off.
Abbott vs. Medtronic: Which Dividend-Paying MedTech Stock is Better?
With both MDT & ABT focusing on their core strengths, the stage is set for a compelling comparison. Let's see which stock is poised for greater upside.
Medtronic plc (MDT) Q4 2025 Earnings Call Transcript
Medtronic plc (NYSE:MDT ) Q4 2025 Earnings Conference Call May 21, 2025 8:00 AM ET Company Participants Ryan Weispfenning - VP and Head of IR Geoff Martha - Chairman and CEO Que Dallara - EVP & President, Diabetes Thierry Pieton - CFO Sean Salmon - EVP and President of Cardiovascular Portfolio Brett Wall - EVP and President of Neuroscience Portfolio Conference Call Participants Travis Steed - Bank of America Robbie Marcus - JPMorgan Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore Joanne Weunsch - Citi Matt Taylor - Jefferies Matt Miksic - Barclays Danielle Antalffy - UBS Shagun Singh - RBC Operator Good morning. I'm Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations, and I appreciate that you're joining us for our Fiscal ‘25 Fourth Quarter Video Earnings Webcast.
